Katzenohr vs Große Lappenfledermaus

Clitopilus passeckerianus compared with Chalinolobus dwyeri

Key Differences

• Katzenohr is Not Evaluated while Große Lappenfledermaus is Vulnerable.

Taxonomic Classification

Rank	Katzenohr	Große Lappenfledermaus
Kingdom	Fungi (Pilze)	Animalia (Tier)
Phylum	Basidiomycota (Ständerpilze)	Chordata (Chordatiere)
Class	Agaricomycetes (Mushrooms)	Mammalia (Säugetiere)
Order	Agaricales (Champignonartige)	Chiroptera (Fledertiere)
Family	Entolomataceae	Vespertilionidae
Genus	Clitopilus	Chalinolobus
Species	Clitopilus passeckerianus	Chalinolobus dwyeri

Conservation Status

Katzenohr

NE — Not Evaluated

Große Lappenfledermaus

VU — Vulnerable

Physical Characteristics

Attribute	Katzenohr	Große Lappenfledermaus
Diet	—	—
Average Lifespan	—	—
Average Length	—	—
Average Weight	—	—

Habitat & Geographic Range

Katzenohr

Habitat

Typically found in forest floors, decomposing wood, and soil ecosystems.

Range

Distributed across Norway and Sweden.

Große Lappenfledermaus

Habitat

Typically found in diverse terrestrial and aquatic ecosystems.

Katzenohr

Clitopilus passeckerianus is a white-rot agaric fungus in the family Entolomataceae notable for its role as a natural producer of pleuromutilin, a diterpenoid antibiotic compound that serves as the biosynthetic precursor for the veterinary and human antibiotic drugs tiamulin and valnemulin, used to treat Mycoplasma infections in livestock. First described from European woodland habitats, the species produces the characteristic Clitopilus fruiting body: a pale, whitish cap with decurrent, crowded gills becoming pinkish at maturity from angular spores, and a farinaceous odor. Its antibiotic-producing capacity makes C. passeckerianus of significant pharmaceutical interest, and biosynthetic studies of pleuromutilin production have informed synthetic chemistry approaches to antibiotic development. The species inhabits temperate deciduous woodland floors in Europe, fruiting in autumn among leaf litter. Discovery of its pleuromutilin biosynthetic pathway has opened avenues for heterologous expression and semi-synthetic modification aimed at developing novel antibiotics to counter antibiotic-resistant bacterial pathogens.